Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab

Trifluridine (FTD)/tipiracil (TPI) plus bevacizumab (Bev) is a promising late-line treatment in metastatic colorectal cancer (mCRC). Although chemotherapy-induced neutropenia (CIN) is a well-known predictor of FTD/TPI efficacy, whether CIN is a predictive marker of efficacy for FTD/TPI + Bev remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamiimabeppu, Daisaku, Osumi, Hiroki, Shinozaki, Eiji, Ooki, Akira, Wakatsuki, Takeru, Yoshino, Koichiro, Sato, Taro, Nakayama, Izuma, Ogura, Mariko, Takahari, Daisuke, Chin, Keisho, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456503/
https://www.ncbi.nlm.nih.gov/pubmed/34594424
http://dx.doi.org/10.3892/ol.2021.13044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456503/
https://www.ncbi.nlm.nih.gov/pubmed/34594424
http://dx.doi.org/10.3892/ol.2021.13044

Ejemplares similares